Immuron Ltd

Immuron Limited is pioneering oral immunotherapy with gut‑targeting polyclonal antibodies, offering a novel, convenient treatment for inflammatory disorders.

Immuron Limited has launched its new product, PROIBS, a treatment for Irritable Bowel Syndrome (IBS), and is also engaging with investors through a virtual conference, highlighting the company’s expansion into the IBS therapeutic space.